# Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)

> **NCT07057089** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 90 (estimated)

## Conditions studied

- Locally Advanced Rectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Camrelizumab
- **DRUG:** CAPOX
- **RADIATION:** Involve-field irradiation
- **RADIATION:** Elective nodal irradiation
- **PROCEDURE:** TME surgery

## Key facts

- **NCT ID:** NCT07057089
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-07-01
- **Primary completion:** 2028-03-01
- **Final completion:** 2030-12-01
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2025-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07057089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07057089, "Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07057089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*